

## 2형 histone deacetylase 차단이 신섬유화 방지에 대한 효과

인제의대 부산백병원 내과<sup>1</sup>, 미생물학, 면역학<sup>2</sup>

옹성문<sup>1</sup>, 이가희<sup>1</sup>, 김태희<sup>1</sup>, 강선우<sup>1</sup>, 김영훈<sup>1</sup>, 서수길<sup>2</sup>

### Blocking Class II Histone Deacetylase Activity Inhibits Renal Fibrosis

Sungmoon Ong<sup>1</sup>, Ga Hee Lee<sup>1</sup>, Tae Hee Kim<sup>1</sup>, Sun Woo Kang<sup>1</sup>, Yeong Hoon Kim<sup>1</sup>, Su-Kil Seo<sup>2</sup>

Inje University Busan Paik Hospital<sup>1</sup>, Microbiology and Immunology<sup>2</sup>

**Introduction:** Fibrosis is the final, common pathological outcome of many chronic kidney diseases. Although histone deacetylases (HDACs) have been reported to be involved in renal fibrosis, it is still unclear which class of HDAC is involved in the pathophysiology of renal fibrosis.

**Objective:** To investigate which class of HDAC is involved in pathogenic renal fibrosis and evaluate anti-fibrotic effect of the defined HDAC inhibitors.

**Methods:** The enzyme activity of class I and class II was examined on TGF-beta 1-induced epithelial-to-mesenchymal transition (EMT) of the human renal proximal tubular epithelial cell line HK-2. By using the pan-HDAC inhibitor (SB939), class I-specific HDAC inhibitor (MS275), and class II-specific HDAC inhibitor (MC1568), we defined the roles of class I and class II enzymes in EMT. To confirm the role of HDACs in vivo, we used the unilateral ureteric obstruction (UUO) model of renal fibrosis.

**Results:** We found that class II enzyme activity was markedly induced on TGF-beta 1-induced EMT but class I enzyme was not induced. Treatment of pan-inhibitor SB939 strongly inhibited TGF-beta 1-induced upregulation of collagen type I and alpha-SMA. Class II-specific inhibitor MC1568 had the similar effects of SB939, but class I-specific inhibitor MS275 did not have the effects. UUO model with SB939 treatment was markedly inhibited accumulation of alpha-SMA and deposition of collagen type I.

**Conclusion:** Our results demonstrate that class II HDACs contribute to renal fibrosis and suggest that class II-selective inhibitors have a therapeutic potential for the treatment of renal fibrosis.

**Key Words:** 히스톤 데아세틸레이즈, 신섬유화  
Histone deacetylase, Renal fibrosis